Observed differences in characteristics of secondary-progressive multiple sclerosis and relapsing-remitting multiple sclerosis patients in the US-based Corrona MS Registry

Objective: To compare characteristics of secondary-progressive (SPMS) vs. relapsing-remitting (RRMS) patients. Background: The clinical course of patients with different MS subtypes is varied. The Corrona MS Registry in collaboration with National Multiple Sclerosis Society studies real-world burden of disease and safety/effectiveness of MS disease modifying therapies (DMTs). Design/Methods: Corrona MS is a US multicenter, observational registry. Means and proportions of enrollment visit characteristics were compared between SPMS vs. RRMS using pair-wise statistical comparisons. Results: As of 1/22/19, 557 RRMS and 80 SPMS patients were enrolled. SPMS vs. RRMS patients were older (57.0, 48.6 years, p Conclusions: SPMS and RRMS patients in Corrona MS demonstrate important differences in age, disease duration, functional system involvement, disease measures, employment status and patient/clinician DMT response impression. Corrona MS can explore phenotypic differences between subtypes, such as active vs. non-active SPMS. Disclosure: Dr. Kantor has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting fees and/or fees for non-CME services (AbbVie, Actelion, Bayer, Biogen, Celgene, Corrona, EMD Serono, Genentech, Mylan, Novartis, and Sanofi).. Dr. Kantor has received research support from Research grants (Actelion).. Dr. Bebo has nothing to disclose. Yes; Accordant, Alexion, Bayer, Biogen MA, Inc., Celgene Corporation, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Serono, TG Therapeutics Yes; Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, Novartis Pharmaceuticals Corporation, PCORIReceived consulting fees, speaker’s bureau and advisory work from Biogen, Celgene, Chugai, EMD Serono, Genetech/Roche, MedDay, Novartis, Sanofi, Genzyme, Teva, and TG Therapeutics Received contracted research from Biogen, Celgene, Chugai, EMD Serono, Genetech/Roche, MedDay, Novartis, Sanofi, Genzyme, Teva, and TG Therapeutics.Dr. Bermel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Genentech, Novartis. Dr. Bermel has received royalty, license fees, or contractual rights payments from intellectual property underlying the Multiple Sclerosis Performance Test, currently licensed to Qr8 Health and Biogen. Dr. Bermel has received research support from Biogen, Genentech, and Novartis. Dr. Greenberg has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Corrona LLC.Dr. Malley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Corrona, LLC.. Dr. McLean has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Corrona, LLC. Dr. Rebello has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Corrona, LLC. Dr. LaRocca has nothing to disclose. Dr. Miller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Accordant Health Services (Caremark), Adamas, BiogenIdec, Celgene, Corrona, EMD Serono, Genzyme/Sanofi, Mallinckrodt, Mapi-Pharma, Novartis, and Roche/Genentech. Dr. Miller has received research support from BiogenIdec, Mallinckrodt (Questcor), Novartis, Roche/Genentech, and MedDay.